Detalhe da pesquisa
1.
[News treatments and survival in lung cancer]. / Nouveaux traitements et survie dans les cancers pulmonaires.
Rev Prat
; 73(1): 7-12, 2023 Jan.
Artigo
em Francês
| MEDLINE | ID: mdl-36820443
2.
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
Respir Med Res
; 83: 101004, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37037058
3.
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
PLoS One
; 18(9): e0291495, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708140
4.
Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases.
Front Oncol
; 12: 787080, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35494085
5.
Immune checkpoint inhibitors and hospitalization at home in France.
Bull Cancer
; 109(1): 89-97, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34785029
6.
Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance of the tumor board decision in the era of immunotherapy.
Cancer Treat Res Commun
; 30: 100508, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35033834
7.
Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion.
Case Rep Nephrol Dial
; 11(3): 376-383, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35111820
8.
Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer.
Cancers (Basel)
; 12(11)2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139612
9.
[First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)]. / Durvalumab et tremelimumab en association à la chimiothérapie en première ligne du cancer bronchopulmonaire non à petites cellules (CBNPC) métastatique sans addiction oncogénique.
Bull Cancer
; 110(11): 1094-1096, 2023 11.
Artigo
em Francês
| MEDLINE | ID: mdl-37758567
10.
[Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer]. / AMM : selpercatinib et pralsetinib cancer bronchique non à petites cellules avec altération de RET.
Bull Cancer
; 108(6): 562-563, 2021 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-34023064